Charles River(US:CRL)2026-02-18 14:21Financial Performance - In 2025, Charles River Laboratories reported total revenue of $4.0 billion, with the Discovery and Safety Assessment (DSA) segment contributing 59.8% of this revenue[20]. - The Research Models and Services (RMS) segment accounted for 21.1% of total revenue, employing approximately 4,140 individuals, including 190 science professionals with advanced degrees[23]. - The Manufacturing segment represented 19.1% of total revenue, with around 2,600 employees[26]. - The backlog for the RMS, DSA, and Manufacturing reportable segments was approximately $640 million, $1.9 billion, and $123 million, respectively, as of December 27, 2025, compared to $685 million, $2.0 billion, and $103 million as of December 28, 2024[122]. Global Operations - Charles River Laboratories operates over 120 sites in more than 20 countries, focusing on optimizing its global footprint by closing or consolidating approximately 12 additional sites over the next two years[20]. - The company has a global footprint with production facilities in 7 countries, strategically located near major biohubs and client concentrations[29]. Service Offerings - The company has a diverse portfolio of services that supports clients from target identification through non-clinical development, enhancing productivity and reducing costs[14]. - The company provides a full range of safety assessment studies required for regulatory submission across all therapeutic areas, establishing itself as a global leader in this field[43]. - The Discovery Services segment provides a full spectrum of services for drug candidate discovery, focusing on major therapeutic areas such as neuroscience, oncology, and immunology[42]. - The company offers a variety of flexible solutions in Research Model Services, including Insourcing Solutions, Genetically Engineered Models and Services, and Research Animal Diagnostic Services[34]. Acquisitions and Growth Strategy - In January 2026, the company acquired assets from K.F. (Cambodia) Ltd., integrating them into its DSA and RMS segments to enhance supply operations[33]. - Acquisitions are a key part of the growth strategy, with notable acquisitions including Explora BioLabs in fiscal 2022 and Noveprim in 2023, aimed at expanding the product and service portfolio[86]. - The company divested its Avian Vaccine Services business in 2022, which represented approximately 7% of the projected revenue for 2025, to focus on more profitable growth opportunities[89]. Employee and Workforce Management - As of December 27, 2025, the company employed approximately 19,700 individuals, with a workforce distribution of 59% in North America, 32% in Europe, and 7% in Asia[109]. - The company reduced its total headcount by approximately 2% since the end of 2024 as part of cost management initiatives[110]. - In fiscal 2025, the company hired over 2,600 people, with a voluntary turnover rate of approximately 10.1%[113]. - The company is committed to providing competitive compensation programs and performs pay equity audits in countries where legally required[118]. Research and Development - The company emphasizes the importance of research models in drug discovery, with a focus on maintaining high-quality standards and biosecurity[30]. - The development of new drugs requires an investment of up to $2.6 billion and exploration of 10,000 to 15,000 drug molecules to produce a single FDA-approved drug[15]. - The company has built a leading position in the production and sale of over 140 different stocks and strains of purpose-bred rodents, essential for drug discovery[23][28]. Safety and Compliance - The Safety Assessment facilities comply with GLP regulations and are regularly inspected by regulatory compliance monitoring authorities, ensuring high standards in safety testing[51]. - The company emphasizes the importance of identifying potential safety risks through a comprehensive offering of toxicology studies, including in vitro and in vivo research models[44]. - The company has established a Data Integrity Compliance Program to ensure proper oversight of electronic records and compliance with regulatory requirements[137]. Technological Advancements - The company is committed to optimizing operations and enhancing client experiences through technology, including the Apollo™ cloud-based platform for real-time data access[82]. - The company develops and implements scientifically-driven products and procedures, including computer software, to enhance its offerings and protect intellectual property rights[139]. Environmental and Safety Initiatives - In 2023, the company initiated a formal Environment, Health, Safety and Sustainability Assessment program, conducting 17 site assessments in the inaugural year[121]. - The company conducted 26 additional site program assessments in 2025 as part of its ongoing safety-first culture journey[121]. - The company emphasizes the importance of a healthy and safe workplace, launching a Safety-First Culture initiative in 2022[121]. Market Opportunities - The market for regulated safety assessment services is estimated to be over 60% outsourced, indicating a significant opportunity for Charles River Laboratories[19]. - The evolving biopharmaceutical R&D business model is expected to drive demand for the company's integrated offerings and expertise, enhancing efficiency and cost-effectiveness for clients[79].